A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Papillex® on the Regression of Abnormal Cervical Cells Caused by HPV
The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis. The main question it aims to answer is: Is there a difference in the proportion of participants with a regression in CIN based on histology or cytology from baseline at day 180 between Papillex® and placebo? Participants will be asked to consume Papillex® or placebo for 180 days, complete questionnaires, a PAP smear, HPV test, and colonoscopy (where applicable).
• Females between 25 and 60 years of age
• Females not of child-bearing potential, defined as those who have undergone a permanent sterilization procedure (e.g. hysterectomy, bilateral oophorectomy or bilateral tubal occlusion) or have been post-menopausal for at least 1 year prior to screening Or,
• Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
⁃ Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), hormone implant (Norplant System) or intrauterine hormone-releasing system
⁃ Double-barrier method
⁃ Intrauterine devices
⁃ Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
⁃ Vasectomized partner, provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success
⁃ Abstinence
• Must have CIN 1 or 2 diagnosis, based on histology within the past 18 months with confirmed abnormal cells based on cytology within 6 months, who are not indicated for treatment or current undergoing treatment
• Willing to provide copies of pathology and cytology reports for eligibility confirmation
• Positive for human papillomavirus (HPV)
• Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
• Willingness to avoid magnetic resonance imaging, computed tomography, X-ray, or other procedures with contrast media injection for 48 hr prior to study visits assessing micronutrient status
• Willingness and ability to complete questionnaires and diaries associated with the study, and to complete all clinic visits and assessments
• Provided voluntary, written, informed consent to participate in the study
⁃ Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)